Viking Therapeutics (STU:1VT) Cyclically Adjusted FCF per Share: €-0.80 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1VT Viking Therapeutics Inc STU:1VT
38 GF Score
Price €29.00
! 3 Warning Signs
View Full Analysis

What is Viking Therapeutics Cyclically Adjusted FCF per Share?

Viking Therapeutics STU:1VT -2.36% 38 Cyclically Adjusted FCF per Share is €-0.80 as of Mar. 2026. GuruFocus rates STU:1VT with a GF Score™ of 38/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Viking Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.853. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.80 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -9.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Viking Therapeutics was -9.80% per year. The lowest was -9.80% per year. And the median was -9.80% per year.

As of today (2026-07-30), Viking Therapeutics's current stock price is €29.00. Viking Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-0.80. Viking Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Viking Therapeutics  (STU:1VT) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Viking Therapeutics Cyclically Adjusted FCF per Share Related Terms


Viking Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Viking Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viking Therapeutics Cyclically Adjusted FCF per Share Chart

Viking Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.59 -0.67 -0.74 -0.75

Viking Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.76 -0.72 -0.73 -0.75 -0.80

STU:1VT vs DYN, CELC, RLAY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Viking Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viking Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viking Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Viking Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


STU:1VT
38GF Score
Viking Therapeutics Inc STU:1VT
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viking Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Viking Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.853/330.2130*330.2130
=-0.853

Current CPI (Mar. 2026) = 330.2130.

Viking Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.168 241.018 -0.230
201609 -0.125 241.428 -0.171
201612 -0.117 241.432 -0.160
201703 -0.137 243.801 -0.186
201706 -0.155 244.955 -0.209
201709 -0.102 246.819 -0.136
201712 -0.111 246.524 -0.149
201803 -0.095 249.554 -0.126
201806 -0.085 251.989 -0.111
201809 -0.077 252.439 -0.101
201812 -0.033 251.233 -0.043
201903 -0.039 254.202 -0.051
201906 -0.079 256.143 -0.102
201909 -0.043 256.759 -0.055
201912 -0.147 256.974 -0.189
202003 -0.054 258.115 -0.069
202006 -0.082 257.797 -0.105
202009 -0.062 260.280 -0.079
202012 -0.062 260.474 -0.079
202103 -0.122 264.877 -0.152
202106 -0.143 271.696 -0.174
202109 -0.119 274.310 -0.143
202112 -0.140 278.802 -0.166
202203 -0.124 287.504 -0.142
202206 -0.165 296.311 -0.184
202209 -0.178 296.808 -0.198
202212 -0.135 296.797 -0.150
202303 -0.294 301.836 -0.322
202306 -0.106 305.109 -0.115
202309 -0.184 307.789 -0.197
202312 -0.162 306.746 -0.174
202403 -0.055 312.332 -0.058
202406 -0.240 314.175 -0.252
202409 -0.178 315.301 -0.186
202412 -0.267 315.605 -0.279
202503 -0.432 319.799 -0.446
202506 -0.364 322.561 -0.373
202509 -0.713 324.800 -0.725
202512 -0.639 324.054 -0.651
202603 -0.853 330.213 -0.853

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.80 mean?
Viking Therapeutics (STU:1VT) has a Cyclically Adjusted FCF per Share of €-0.80 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Viking Therapeutics and its competitors.
Is Viking Therapeutics' Cyclically Adjusted FCF per Share too high?
Viking Therapeutics' current Cyclically Adjusted FCF per Share is €-0.80. Overall, Viking Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Viking Therapeutics' Cyclically Adjusted FCF per Share compare to DYN and CELC?
Viking Therapeutics' Cyclically Adjusted FCF per Share of €-0.80 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Viking Therapeutics and its competitors. Viking Therapeutics's current Cyclically Adjusted FCF per Share is €-0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viking Therapeutics stock overvalued right now?
Viking Therapeutics (STU:1VT) has a current Cyclically Adjusted FCF per Share of €-0.80. The current Cyclically Adjusted FCF per Share is €-0.80. Viking Therapeutics' overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Viking Therapeutics (STU:1VT), the current Cyclically Adjusted FCF per Share is €-0.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viking Therapeutics Business Description

Other Exchanges VKTX:USA1VKTX:Italy0VQA:UK
Address 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
38GF Score

Get the complete analysis for STU:1VT

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.00
Price